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The synthesis and characterization of a novel class of benzofuran-isoxazole 7a-j hybrid heterocyclic unit are described 
and their antimicrobial activities evaluated. The antimicrobial investigation studies reveal that the majority of the final target 
compounds exhibit moderate to excellent activity against tested microbes. Among the compounds screened 7b, 7a and 7i 
have shown potent activity and compounds 7h, 7c, 7f show good activity compared to standard drugs Gentamicin and 
Nystatin. 
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Benzofuran and its derivatives either natural or 
synthetic have been reported1,2 to exhibit diverse 
biological activities such as antibacterial3,4, antimicrobial5, 
antifungal6, antitumor7, anticonvulsant, anti-HIV8, 
antitubercular9, anti-inflammatory10, antidiabetic11, 
antidepressant12, and antineophobic13 and in the 
treatment of asthma, rheumatism and ulcers14. 
Furthermore, certain derivatives of benzofuran present in 
natural products show high cytotoxicity15. 
On other hand isoxazoles either natural or synthetic 
have been drawing significant interest from medicinal 
and organic chemists owing to their notable biological 
activities16. Isoxazoles are playing important role in 
heterocyclic chemistry as pharmacophores and 
extensively used as synthons in the field of organic 
chemistry. Isoxazole forms the basis for several drugs 
such as leflunomide, valdecoxib and zonisamide. 
In continuation to our previous work in discovering 
potential antimicrobial benzofurans4,3 and 
isoxazoles2,16, this work directed towards the synthesis 
of a diverse series of novel benzofuran-isoxazole 
derivatives of biological interest. 
 
Results and Discussion 
 
Chemistry 
As shown in Scheme I, benzofuran based 3,5-
disubstituted isoxazoles (7a-j) were synthesized by a 
4-step protocol. Compound 2 was obtained by the 
reaction of 1-(2,5-dihydroxyphenyl)ethanone (1) with 
3-bromoprop-1-yne in the presence of K2CO3 and 
acetone. The key intermediate compound 4 was 
obtained 96% yield by the reaction of acetylinic ortho 
hydroxyl acetophenone (2) with phenacylbromide (3). 
This was confirmed by 1H-NMR spectra which 
showed characteristic peaks at δ 4.74 (d, J = 2.4 Hz, 
2H) and at δ 2.53 (d, J = 2.27 Hz, 1H) indicates 
presence of acetylenic benzofuran. This was further 
confirmed by MASS spectra which gave base peak  
at m/z 291 [M+H]+ corresponding to the molecular 
weight of compound 4. Different substituted 
aldoximes (6a-j) were prepared by reacting aldehydes 
(5a-j) with hydroxylamine hydrochloride. The in situ 
generated nitrile oxides from oxime (6a-j) underwent 
a 1,3-dipolar cycloaddition with alkyne (4) to give the 
corresponding isoxazoles (7a-j). In 1H-NMR spectra 
peak between δ 6.85 to δ 7.01 indicates the formation 
of isoxazole ring. This was also confirmed by 13C-
NMR spectra which showed characteristic peak of 
isoxazole between δ 97.2 to δ 97.4. The structures of 
the newly synthesized target molecules were 





The targeted novel benzofuran-isoxazoles (7a-j) 
were tested for their antibacterial activity against four 




gram positive bacteria vize Micrococcus luteus, 
Methicillin-resistant Staphylococcus aureus, Bacillus 
subtilis, Bacillus cereus & four gram negative 
bacteria vize Pseudomonas aeruginosa, Klebsiella 
pneumoniae, Escherichia coli and Proteus vulgaris 
using Gentamicin sulphate as standard drug. All the 
tested compounds displayed excellent to moderate 
activity against tested bacterial strains (Table I). 
Among the compounds 7b, 7a, 7i, 7h and 7c were 
shown potent active. It was attracting that compounds 
with strong electron withdrawing group like NO2 of 
phenyl ring attached to isoxazole may increasing the 
antibacterial activity than other aryl substituted 
isoxazole. The compounds 7d, 7e, 7f, 7g and 7j were 




The target benzofuran-isoxazoles (7a-j) were also 
screened for antifungal activity studies against three 
dermatophytes vize, Microsporum canis, Microsporum 
gypseum and Epidermophyton floccosum. According to 
the results obtained (Table II) among all screened 
analogues, 7b, 7a, 7i, 7h, 7c and 7f have shown more 
active against tested fungal strains compared to standard 
drug Nystatin. Compounds 7d and 7e exhibited 
moderate active. 
Experimental Section 
The melting points were measured in open capillaries 
and are uncorrected. The IR spectra were recorded on a 
Perkin−Elmer 337 grating IR spectrophotometer for 
solid samples pelleted in KBr. The NMR spectra were 
obtained on Bruker AV-400 and AV-300 NMR 
spectrometers for CDCl3 solutions. The chemical shifts 
were measured in ppm against internal TMS. Electron 
Spray Ionization (ESI) mass spectra were recorded  
on a QSTARXL hybrid MS system (Applied Bio  
Systems) under electro spray ionization. Thin layer 
chromatography was carried out on Merck TLC silica 
gel 60 F254 plates. The spots were visualized in UV 
light at 254 nm. Column chromatography was 
performed on a Merck silica gel 60A (100–200 mesh). 
 
Synthesis of compound 2 
Compound 1 (2 g, 0.0131 mol) was dissolved in 
dry acetone and was added K2CO3 (1.81 g, 0.0131 
mol) and 3-bromoprop-1-yne (1.56 g, 0.0131 mol). 
This reaction mixture was heated at reflux 
temperature for 8 hours and monitored by TLC. After 
consumption of starting materials the reaction mixture 
was allowed to room temperature then excess acetone 
was removed. The crude was diluted with water and 
extracted with ethyl acetate. The combined organic 
layer was subjected to reduced pressure to remove 
 
 
Scheme I — Synthesis of benzofuran based 3,5-disubstituted isoxazoles 7a-j 
 




excess solvent. The crude obtained was purified by 
column chromatography to offered 1-(2-hydroxy-5-
(prop-2-yn-1-yloxy)phenyl)ethanone 2. 
IR (KBr, max cm-1): 3408, 2345, 1642. White solid, 
Yield 84%, mp 184-186°C. 1H NMR (300 MHz, 
CDCl3): 12.4 (s, 1H), 7.62 (dd, J = 7.07, 2.3 Hz, 1H), 
6.40–6.40 (m, 2H), 4.73 (d, J = 2.3 Hz, 2H), 2.54 (s, 
3H), 2.53 (d, J = 2.28 Hz, 1H). MS: m/z 191 [M+H]+. 
 
Synthesis of (3-methyl-5-(prop-2-yn-1-
yloxy)benzofuran-2-yl) (phenyl)methanone, 4 
In dry acetone compound 2 (2.5 g, 0.013 mol) was 
dissolved followed by K2CO3 (2.72 g, 0.019 mol), 2-
bromo-1-phenylethanone (2.61 g, 0.013) was added and 
was stirred at room temperature for 20 hours. After 
completion of reaction as indicated by TLC, excess 
acetone was removed under reduced pressure then 
diluted with water and extracted with ethyl acetate. The 
organic layer was concentrated to get crud product 
which was subjected to column chromatography which 
offered pure compound 4 in 96% yield. IR spectrum, ν, 
cm-1: 1664. White solid, mp 199-201°C. 1H NMR  
(300 MHz, CDCl3): 7.64-7.22 (m, 6H), 6.44–6.41  
(m, 2H), 4.74 (d, J = 2.4 Hz, 2H), 2.56 (s, 3H), 2.53  
(d, J = 2.27 Hz, 1H). MS: m/z 291 [M+H]+. 
 
Procedure for the preparation of aldoximes, 6a-j 
To a solutions of aldehyde 5a-j (1 eq) in methanol 
was added hydroxylamine hydrochloride (1 eq) 
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75 30 28 27 27 26 28 29 27 
100 33 31 30 30 30 32 32 31 
7b 
75 32 31 28 30 29 30 28 28 
100 35 34 31 33 33 34 32 32 
7c 
75 20 19 20 18 19 20 17 21 
100 23 23 23 21 22 24 21 24 
7d 
75 15 15 16 15 14 13 14 12 
100 17 18 20 18 18 17 17 16 
7e 
75 13 13 12 13 11 12 14 12 
100 17 16 16 16 14 15 18 15 
7f 
75 18 17 20 17 18 17 16 20 
100 22 20 23 21 22 22 20 23 
7g 
75 11 11 12 12 10 09 11 09 
100 14 13 16 15 13 13 15 12 
7h 
75 23 21 22 21 20 21 23 21 
100 26 24 25 24 23 24 26 24 
7i 
75 29 26 25 24 23 23 27 26 
100 33 29 28 27 26 26 30 29 
7j 
75 09 08 NA 08 07 08 NA 08 
100 12 12 NA 11 10 11 NA 10 
Zentamicin 
75 28 31 31 32 27 27 30 29 
100 31 33 33 35 31 30 33 32 
Methicillin-resistant Staphylococcus aureus (MRSA), No Activity (NA). 
 












75 25 20 19 
100 28 23 22 
7b 
75 26 23 23 
100 29 27 26 
7c 
75 19 16 16 
100 22 19 18 
7d 
75 13 11 09 
100 16 14 12 
7e 
75 08 05 06 
100 11 08 09 
7f 
75 06 08 08 
100 09 10 11 
7g 
75 08 12 07 
100 10 15 11 
7h 
75 19 17 17 
100 23 21 19 
7i 
75 22 18 17 
100 25 21 20 
7j 
75 09 11 10 
100 12 14 13 
Nystatin
75 25 20 20 
100 28 24 23 
 




followed by sodium acetate (1.5 eq). The resulting 
reaction mixture was stirred at room temperature for 3 
hours. After completion of the reaction, the reaction 
mixture was quenched by adding crushed ice and the 
precipitate formed was isolated by filtration, washed 
with pet ether, and dried to afford substituted 
aldoximes 6a-j. 
 
Synthesis of benzofuran based 3,5-disubstituted 
isoxazoles, 7a-j 
To a solution of benzaldehyde oximes 6a-j (100 
mg, 1 eq) in DMF was added N-chloro succinamide 
(1 eq) for chlorination, the resulting mixture was 
stirred at room temperature for 30 minutes. The 
reaction mixture was cooled to 0 °C and slowly added 
catalytic amount of 1,8-Diazabicyclo[5.4.0]undec-7-
ene (DBU) (0.2eq) followed by compound 4 (1 eq). 
This resulting reaction mixture was stirred for 4 hours 
at room temperature. After consumption of the 
starting materials, as indicated by TLC, ice-cold water 
was added to the reaction mixture, precipitate so 
obtained was filtered, washed with water and cold 
MeOH to afford the pure substituted benzofuran 
based 3,5-disubstituted isoxazoles 7a-j in excellent 




IR (KBr, max cm-1): 1656 (C=O). 1H NMR (400 
MHz, CDCl3): 8.38-8.28 (m, 1H), 8.27-8.18 (m, 2H), 
8.17-7.98 (m, 2H), 7.82-7.77 (m, 1H), 7.64-7.42 (m, 
4H), 7.22-7.11 (m, 2H), 6.86 (s, 1H), 5.37 (s, 2H), 
2.61 (s, 3H). 13C NMR (100 MHz, CDCl3): 185.7, 
167.7, 159.1, 157.9, 155.8, 147.9, 145.6, 138.5, 138.0, 
132.3, 129.8 (2C), 128.5 (2C), 127.5, 126.7, 125.8, 
123.8, 123.3, 122.2, 120.7, 115.2, 114.2, 97.3, 61.4, 




IR spectrum, ν, cm-1: 1653 (C=O). 1H NMR (400 
MHz, CDCl3): 8.42 (d, J = 7.6 Hz, 2H), 8.10-7.96 (m, 
4H), 7.62-7.42 (m, 4H), 7.23-7.17 (m, 2H), 6.85 (s, 
1H), 5.38 (s, 2H), 2.61 (s, 3H). 13C NMR (100 MHz, 
CDCl3): 185.6, 167.8, 159.1, 158.8, 155.7, 147.1, 
145.6, 141.1, 138.5, 133.0, 129.8 (2C), 128.6 (2C), 
127.4, 125.5 (2C), 123.5, 122.2, 120.7, 120.5 (2C), 




IR (KBr, max cm-1): 1652 (C=O). 1H NMR (400 
MHz, CDCl3): 8.10-8.06 (m, 2H), 7.71 (s, 1H), 7.68 
(s, 1H), 7.59 (t, J = 7.4 Hz, 1H), 7.55-7.46 (m, 4H), 
7.45-7.42 (m, 1H), 7.23 (d, J = 2.2 Hz, 1H), 7.18 (dd, 
J = 8.8, 2.3 Hz, 1H), 6.90 (s, 1H), 5.39 (s, 2H), 2.60 
(s, 3H). 13C NMR (100 MHz, CDCl3): 185.6, 167.8, 
159.0, 158.4, 155.7, 148.0, 145.5, 137.7, 138.4, 132.3, 
129.9 (2C), 128.6 (2C), 128.2 (2C), 127.4, 126.6, 
123.6, 122.2, 121.6 (2C), 114.2, 97.2, 61.6, 10.1. MS: 




IR (KBr, max cm-1): 1647 (C=O). 1H NMR (400 
MHz, CDCl3): 8.18-7.99 (m, 3H), 7.63-7.38 (m, 7H), 
7.15 (s, 1H), 7.03 (d, J = 8.28 Hz, 1H), 6.86 (s, 1H), 
5.36 (s, 2H), 2.61 (s, 3H). 13C NMR (100 MHz, 
CDCl3): 185.6, 167.8, 159.2, 158.4, 155.6, 148.5, 
145.5, 138.4, 137.6, 135.6, 132.3, 130.8, 129.9 (2C), 
129.5, 129.1, 128.6 (2C), 127.4, 123.6, 122.1, 120.7, 




IR (KBr, max cm-1): 1649 (C=O). 1H NMR (400 
MHz, CDCl3): 8.09-7.96 (m, 3H), 7.78-7.51 (m, 7H), 
7.19 (s, 1H), 7.06 (d, J = 8.32 Hz, 1H), 6.90 (s, 1H), 
5.40 (s, 2H), 2.62 (s, 3H). 13C NMR (100 MHz, 
CDCl3): 185.3, 168.1, 158.9, 158.1, 157.5, 148.1, 
145.2, 139.1, 137.4, 135.1, 131.9, 131.0, 130.0 (2C), 
129.4, 128.9, 128.5 (2C), 127.3, 123.4, 121.9, 121.0, 




IR (KBr, max cm-1): 1651 (C=O). 1H NMR (400 
MHz, CDCl3): 8.09-8.05 (m, 2H), 7.70 (s, 1H), 7.67 
(s, 1H), 7.61 (t, J = 7.6 Hz, 1H), 7.53-7.46 (m, 4H), 
7.45-7.41 (m, 1H), 7.22 (d, J = 2.4 Hz, 1H), 7.20 (m, 
J = 8.6, 2.3 Hz, 1H), 6.96 (s, 1H), 5.37 (s, 2H), 2.59 
(s, 3H). 13C NMR (100 MHz, CDCl3): 185.5, 167.9, 
Table III — Physical data of compounds 7a-j 
Compd Physical State Yield (%) m.p. (°C) 
7a Light yellow solid 84 147-149 
7b Light yellow solid 75 157-159 
7c White solid 88 86-88 
7d White solid 90 77-79 
7e White solid 80 72-73 
7f Light yellow solid 95 104-106 
7g White solid 93 112-114 
7h White solid 90 95-97 
7i White solid 83 119-121 
7j White solid 86 126-128 




159.3, 158.4, 155.4, 148.6, 145.9, 145.1, 138.3, 132.6, 
132.1 (2C), 129.8 (2C), 128.5 (2C), 127.4, 124.3, 
123.7, 122.3, 121.6 (2C), 114.1, 97.3, 61.7, 10.4. MS: 




IR (KBr, max cm-1): 1655 (C=O). 1H NMR (400 
MHz, CDCl3): 8.17-8.05 (m, 2H), 7.69-7.58 (m, 5H), 
7.58-7.50 (m, 2H), 7.50-7.43 (m, 1H), 7.27-7.24 (m, 
1H), 7.22-7.19 (m, 1H), 7.01 (s, 1H), 5.39 (s, 2H), 
2.62 (s, 3H). 13C NMR (100 MHz, CDCl3): 185.6, 
167.8, 159.2, 158.4, 155.6, 148.5, 145.5, 138.4, 137.5, 
132.9, 132.8, 132.5, 132.3, 129.9 (2C), 128.6 (2C), 
127.4, 123.6, 122.1, 121.9, 121.8, 114.2, 97.2, 61.6, 




IR (KBr, max cm-1): 1654 (C=O). 1H NMR (400 
MHz, CDCl3): 8.10-8.06 (m, 2H), 7.80 (s, 1H), 7.70 
(s, 1H), 7.61 (t, J = 7.48 Hz, 1H), 7.58-7.47 (m, 4H), 
7.44-7.40 (m, 1H), 7.21 (d, J = 2.4 Hz, 1H), 7.13 (dd, 
J = 8.6, 2.3 Hz, 1H), 6.92 (s, 1H), 5.39 (s, 2H), 3.86 
(s, 3H), 2.61 (s, 3H). 13C NMR (100 MHz, CDCl3): 
185.5, 166.9, 158.8, 158.1, 156.8, 147.8, 146.0, 138.7, 
138.1, 132.3, 130.2 (2C), 128.6 (2C), 128.1 (2C), 
127.3, 126.5, 123.4, 122.1, 121.5 (2C), 114.3, 97.3, 




IR (KBr, max cm-1): 1653 (C=O). 1H NMR (400 
MHz, CDCl3): 8.07-7.98 (m, 2H), 7.75 (s, 1H), 7.70 
(s, 1H), 7.58 (t, J = 7.3 Hz, 1H), 7.56-7.47 (m, 4H), 
7.39-7.36 (m, 1H), 7.20 (d, J = 2.4 Hz, 1H), 7.16 (dd, 
J = 8.6, 2.4 Hz, 1H), 6.95 (s, 1H), ), 5.36 (s, 2H), 3.88 
(s, 3H), 2.61 (s, 3H). 13C NMR (100 MHz, CDCl3): 
185.7, 167.4, 159.1, 157.2, 155.1, 148.1, 146.0, 149.9, 
137.8, 132.5, 131.9 (2C), 129.8 (2C), 128.4 (2C), 
127.7, 124.3, 123.6, 122.1, 121.5 (2C), 114.3, 97.4, 
61.7, 56.7, 10.4. MS: m/z 440 [M+H]+. 
 
(3-Methyl-5-((3-(p-tolyl)isoxazol-5-yl)methoxy) 
benzofuran-2-yl)(phenyl)methanone, 7j: IR (KBr, 
max cm-1): 1658 (C=O). 1H NMR (400 MHz, CDCl3): 
8.06-7.97 (m, 3H), 7.63-7.38 (m, 7H), 7.18 (s, 1H), 
7.08 (d, J = 8.28 Hz, 1H), 6.90 (s, 1H), 5.35 (s, 2H), 
2.58 (s, 3H), 2.45 (s, 3H). 13C NMR (100 MHz, 
CDCl3): 185.4, 167.5, 158.9, 157.4, 155.9, 148.1, 
146.2, 138.1, 137.6, 134.4, 131.2, 130.7, 129.8 (2C), 
129.3, 129.3, 128.5 (2C), 127.7, 123.5, 122.2, 120.8, 
113.9, 97.3, 61.5, 23.5, 10.3. MS: m/z 424 [M+H]+. 
 
Conclusions 
A new series of benzofuran-isoxazole 
heterocyclics 7a-j were synthesized in high yields 
and characterized by different spectroscopic 
techniques. These synthesized molecules were 
screened for antimicrobial activity and demonstrated 
excellent activity against tested bacterial and fungal 
strains. The highest activities were found for 
compounds 7b, 7a, 7i, 7h, 7c and 7f. These results 
positively encouraged us for further developing 
novel bioactive agents. 
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